Brown, R. C., Cruz, K., Kalfa, T. A., Kuypers, F. A., Saraf, S. L., Estepp, J. H., … Telen, M. J. (2021). FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after multiple daily doses in a phase 1 study of patients with sickle cell disease. In BRITISH JOURNAL OF HAEMATOLOGY (Vol. 193, pp. 23–24).

Brown, R Clark, Kimberly Cruz, Theodosia A. Kalfa, Frans A. Kuypers, Santosh L. Saraf, Jeremie H. Estepp, Luke R. Smart, et al. “FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after multiple daily doses in a phase 1 study of patients with sickle cell disease.” In BRITISH JOURNAL OF HAEMATOLOGY, 193:23–24, 2021.

Brown RC, Cruz K, Kalfa TA, Kuypers FA, Saraf SL, Estepp JH, et al. FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after multiple daily doses in a phase 1 study of patients with sickle cell disease. In: BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 23–4.

Brown, R. Clark, et al. “FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after multiple daily doses in a phase 1 study of patients with sickle cell disease.” BRITISH JOURNAL OF HAEMATOLOGY, vol. 193, 2021, pp. 23–24.

Brown RC, Cruz K, Kalfa TA, Kuypers FA, Saraf SL, Estepp JH, Smart LR, Malik P, Lerman M, Mayer R, Ribadeneira MD, Forsyth S, Schroeder P, Wu E, Kelly P, Telen MJ. FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after multiple daily doses in a phase 1 study of patients with sickle cell disease. BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 23–24.